The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer

Abstract excerpt

Bladder cancer is one of the most common cancers worldwide. A number of genetic and epigenetic alterations have been identified in bladder tumorigenesis, including activating mutations in fibroblast growth factor receptor 3 (FGFR3) and RAS family genes. In this study, we have analysed the mutational spectrum of FGFR3 and RAS genes (HRAS, NRAS and KRAS). We have also studied the relationship between mutations. A...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bladder and Urothelial Cancer Treatments
• Share to Epigenetics and DNA Methylation
• Share to Fibroblast Growth Factor Research